论文部分内容阅读
目的:探讨负荷剂量阿托伐他汀对心肌梗死急性期患者疗效的影响,为临床合理用药提供参考。方法:选取2012年2月—2014年12月间收治的急性心肌梗死住院治疗患者86例,按照随机数字表将患者分为观察组和对照组,每组43例;分别给予负荷剂量(入院12 h内单次口服80 mg,后20 mg/d)阿托伐他汀和常规剂量(20mg/d)阿托伐他汀治疗;比较两组患者治疗前后及末次随访的C-反应蛋白和血脂的测得值,以及心室重塑超声指标(LVEF、LVESV、LVEDV和WMSI)测得值和并发症的发生率。结果:两组患者治疗后C-反应蛋白值均有不同程度下降,其中观察组下降幅度大于对照组(P<0.05),血脂下降幅度大于对照组(P<0.05),心源性病死和心梗复发率稍低于对照组(P>0.05)。结论:采用负荷剂量阿托伐他汀治疗心肌梗死急性期患者的疗效和安全性优于常规剂量的疗效。
Objective: To investigate the effects of atorvastatin on the curative effect of patients with acute myocardial infarction (AMI) and to provide reference for clinical rational drug use. Methods: A total of 86 hospitalized patients with acute myocardial infarction (AMI) admitted from February 2012 to December 2014 were selected and divided into observation group and control group according to random number table. Each group was given 43 doses of loading (admission 12 h in a single oral 80 mg, 20 mg / d after atorvastatin and conventional dose (20mg / d) atorvastatin treatment; two groups of patients before and after treatment and the last follow-up of C-reactive protein and serum lipids measured Values, and ventricular remodeling ultrasound parameters (LVEF, LVESV, LVEDV and WMSI) measured values and the incidence of complications. Results: The levels of C-reactive protein decreased after treatment in both groups, in which the decreasing rate in the observation group was larger than that in the control group (P <0.05), and the decreasing extent of the lipids was greater than that in the control group (P <0.05) The recurrence rate of stems was slightly lower than that of control group (P> 0.05). Conclusion: The efficacy and safety of atorvastatin loading load in the treatment of patients with acute myocardial infarction is better than that of conventional dose.